

dihydrocodeine/caffeine/APAP capsule (TREZIX)
dihydrocodeine/caffeine/APAP tablet
DIVORAH (dihydrocodeine/caffeine/APAP tablet)

Diagnosis Considered for Coverage:

- Moderate to moderately severe pain

Coverage Criteria:

For diagnosis listed above:

- Inadequate response or intolerable side effect to 2 preferred immediate-release opioid medications, **and**
- Dose does not exceed 10 capsules per day

Coverage Duration: 7 days

Effective: 2/06/2019

Posted: 2/15/2019